The company, which specialises in end-to-end supply chain services, made the decision to invest in line with increasing demand for its manufacturing & packaging capabilities from its growing pharma and biotech client portfolio.
The investment includes equipment for the company’s blister and bottle lines, vial labelling, stability chambers and cold storage capacity.
Vincent Dunne, CEO at Wasdell, said: “We are committed to continual investment into our capabilities. In addition to meeting increased demand, our new packaging equipment will allow us to maintain the swift turnaround times and flexible service we are well known for in the industry.
This investment is at an exciting stage in the growth of the group, and part of a long-term investment plan to expand our capacity & capabilities.
The equipment will be installed across all Wasdell’s sites in the UK and Ireland, including the recently opened Dundalk facility.
Martin Tedham, Wasdell Group Chairman added “The investment will also support our expanding customer base , particularly US life sciences companies, as they continue to source a provider that can readily navigate the European market and specialises in small-mid batch sizes.”
The Wasdell Group offers services across manufacturing, packaging and storage and distribution.
